nach oben

Clinical and Translational Oncology

Erschienen in:

01.01.2015 | Brief Research Article

MiR-215/192 participates in gastric cancer progression

verfasst von: Y. J. Xu, Y. Fan

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Growing evidence indicates that microRNAs (miRNAs) play critical roles in cancer progression. However, the role of miR-215 or miR-192 in gastric carcinogenesis remains unclear at this point.

Materials and methods

Quantitative real-time PCR analysis is used to detect the expression levels of miR-215 or -192. Matrigel invasion assay is used to explore the effects of miR-215 or -192 on gastric cancer cells invasion ability. Statistical analysis is carried out by SPSS 19.0 software.

Results

MiR-215/192 is significantly up-regulated in gastric cancer tissues from gastrectomy. The up-regulation of miR-215 or -192 was related with the clinical characteristics of gastric cancer, such as lymph node metastasis. Inhibition of miR-215/192 significantly suppressed gastric cancer cell invasion. Statistical analysis indicated that the expression of miR-215 or -192 may be a potential candidate biomarker for gastric cancer prognosis.

Conclusions

These data suggest that frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.PubMedCrossRef

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRef

Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005;15:200–5.PubMedCrossRef

Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–71.PubMedCrossRef

Tsai NP, Lin YL, Wei LN. MicroRNA mir-346 targets the 5′-untranslated region of receptor-interacting protein 140 (RIP140) mRNA and up-regulates its protein expression. Biochem J. 2009;424:411–8.PubMedCrossRef

Moretti F, Thermann R, Hentze MW. Mechanism of translational regulation by miR-2 from sites in the 5′ untranslated region or the open reading frame. RNA. 2010;16:2493–502.PubMedCentralPubMedCrossRef

Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol. 2009;44:556–61.PubMedCrossRef

Ding L, Xu YJ, Zhang W, Deng Y, Si M, Du Y, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010;20:784–93.PubMedCrossRef

10.

Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010;70:2339–49.PubMedCrossRef

11.

Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;12(6):e1000879.CrossRef

12.

Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010;46:2295–303.PubMedCrossRef

13.

Feng R, Chen X, Yu Y, Su L, Yu B, Li J, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010;298:50–63.PubMedCrossRef

14.

Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272–86.PubMedCrossRef

15.

Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.PubMedCentralPubMedCrossRef

16.

Feng L, Xie Y, Zhang H, Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2012;29:856–63.PubMedCrossRef

17.

Li X, Zhang Y, Shi Y, Dong G, Liang J, Han Y, et al. MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med. 2011;15:1887–95.PubMedCrossRef

18.

Song G, Zeng H, Li J, Xiao L, He Y, Tang Y, et al. miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. Biol Pharm Bull. 2010;33:1822–7.PubMedCrossRef

19.

Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med. 2012;3:560–6.PubMedCentralPubMed

20.

Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 2013;34:2231–9.PubMedCrossRef

21.

Li S, Gao J, Gu J, Yuan J, Hua D, Shen L. MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery. Med Oncol. 2013;30:549.PubMedCrossRef

22.

Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer. 2011;10:340–7.PubMedCentralPubMedCrossRef

23.

Liang H, Li Y, Luo RY, Shen FJ. MicroRNA-215 is a potential prognostic marker for cervical cancer. J Huazhong Univ Sci Technol Med Sci. 2014;34:207–12.PubMedCrossRef

24.

Deng Y, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, et al. MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett. 2014;342:27–35.PubMedCrossRef

25.

Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008;68:10105–12.PubMedCrossRef

26.

Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008;68:10094–104.PubMedCentralPubMedCrossRef

27.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18:367–81.PubMedCentralPubMedCrossRef

28.

Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010;9:96.PubMedCentralPubMedCrossRef

29.

Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidylate synthase regulation. Mol Cancer Ther. 2010;9:2265–75.PubMedCrossRef

30.

Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, et al. MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010;97:853–61.PubMedCrossRef

31.

Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012;16:2655–66.PubMedCrossRef

32.

Senanayake U, Das S, Vesely P, Alzoughbi W, Fröhlich LF, Chowdhury P, et al. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis. 2012;33:1014–21.PubMedCrossRef

33.

Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–46.PubMedCrossRef

34.

Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y, et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene. 2011;30:1577–85.PubMedCrossRef

Titel: MiR-215/192 participates in gastric cancer progression
verfasst von: Y. J. Xu
Y. Fan
Publikationsdatum: 01.01.2015
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 1/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-014-1194-6

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MiR-215/192 participates in gastric cancer progression

Abstract

Introduction

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology

Interleukin-17 is a favorable prognostic marker for colorectal cancer

Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53

Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy

EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma

Acknowledgement to Referees 2014

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie